Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
27 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For May 4, 2022

By Benzinga Insights
Today, 9:57 PM
  Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

ABC

Read More
2 minute read
  • Earnings

Looking Into Nu Skin Enterprises’s Return On Capital Employed

By Benzinga Insights
Today, 9:57 PM
Nu Skin Enterprises (NYSE:NUS) brought in sales totaling $673.44 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 118.56%, resulting in a loss of $9.23 million.

NUS

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

DA Davidson Maintains Neutral on Nu Skin Enterprises, Raises Price Target to $50

By Benzinga Newsdesk
Today, 9:57 PM
DA Davidson analyst Linda Bolton Weiser maintains Nu Skin Enterprises (NYSE:NUS) with a Neutral and raises the price target from $47 to $50.

NUS

Read More
25 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For November 3, 2021

By Benzinga Insights
Today, 9:57 PM
  Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.

AAWW

Read More
1 minute read
  • News

Nu Skin Enterprises Strategic Investment Arm Rhyz Analytical Labs Launches Analytical Testing Services for Beauty and Wellness Companies

By Michael Horton
Today, 9:57 PM
Rhyz Analytical Labs today announced the availability of its testing services for beauty and wellness companies to assess product safety and effectiveness through trusted, timely and accurate results.

NUS

Read More
2 minute read
  • News

5 Value Stocks To Watch In The Consumer Defensive Sector

By Benzinga Insights
Today, 9:57 PM
What are Value Stocks?

BG

Read More
1 minute read
  • Analyst Ratings
  • Pre-Market Outlook
  • Price Target

10 Biggest Price Target Changes For Wednesday

By Lisa Levin
Today, 9:57 PM
Goldman Sachs lowered the price target on Nucor Corporation (NYSE: NUE) from $123 to $108. Nucor shares fell 3.6% to $95.15 in pre-market trading.

BHVN

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

DA Davidson Maintains Neutral on Nu Skin Enterprises, Lowers Price Target to $47

By Benzinga Newsdesk
Today, 9:57 PM
DA Davidson analyst Linda Bolton Weiser maintains Nu Skin Enterprises (NYSE:NUS) with a Neutral and lowers the price target from $61 to $47.

NUS

Read More
1 minute read
  • Guidance
  • Movers
  • News
  • Trading Ideas

Nu Skin Cuts Q3 Revenue Outlook As Delta Variant Disrupts Sales

By Shivani Kumaresan
Today, 9:57 PM
Nu Skin Enterprises Inc (NYSE:NUS) expects third-quarter revenue of $637 million -$642 million (consensus $710.11 million), down from the previous guidance…

NUS

Read More
1 minute read
  • Guidance
  • News

Nu Skin Enterprises Lowers Q3 Sales Guidance from $700.00M-730.00M to $637.00M-642.00M

By Luke J Jacobi
Today, 9:57 PM
Nu Skin Enterprises (NYSE:NUS) lowers Q3 sales outlook from $700.00 million-730.00 million to $637.00 million-642.00 million.

NUS

Posts navigation

Previous 1 2 3 4 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service